New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Perrigo Company plc (NYSE: PRGO) between February 27, 2023 and November 4, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Perrigo securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
LAW
newsfilecorp.com
• Dec. 7, 2025
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), of the important January 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
INSP
newsfilecorp.com
• Dec. 7, 2025
Intersection of 28.9m at 2.5g/t AuEq just 200m from surface offers potential for additional resource growth; Follow-up drilling to start next week Intersection of 28.9m at 2.5g/t AuEq just 200m from surface offers potential for additional resource growth; Follow-up drilling to start next week
CYGGF
globenewswire.com
• Dec. 7, 2025
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
LAW
newsfilecorp.com
• Dec. 7, 2025
With the Federal Reserve likely to cut interest rates this week, income investments are essential to helping investors navigate another low-rate era. Two ETFs already offer yields that are 2 to 3 times greater than the S&P 500 average.
SCHD
fool.com
• Dec. 7, 2025
NEW YORK , Dec. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of agilon health, inc. (NYSE: AGL) resulting from allegations that agilon health may have issued materially misleading business information to the investing public.
AGL
prnewswire.com
• Dec. 7, 2025
Peloton continues to explore new initiatives to reduce costs and boost sales, but revenue is still declining. Management is guiding for some improvement in certain areas for 2026.
PTON
fool.com
• Dec. 7, 2025
New York City-based Engine Capital Management bought 14.2 million shares of Avantor in the third quarter. The position value increased by $172 million from the prior period.
AVTR
fool.com
• Dec. 7, 2025
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced new clinical and translational data from the ongoing clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) in patients with large B-cell lymphoma (LBCL), which were presented today in two oral presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. As of the data cutoff date of September 5, 2025, ronde-cel continued to demonstrate robust clinical responses with a manageable safety profile appropriate for outpatient administration. A 93% overall response rate, a 76% complete response rate, and median progression-free survival of 18 months were reported for patients with relapsed and/or refractory (R/R) LBCL in the third- or later-line (3L+) setting. Patients evaluated in the second-line (2L) setting (94% with difficult-to-treat primary refractory disease) achieved an 83% overall response rate and a 61% complete response rate, and 70% of patients with a complete response remained in complete response at 6 months or longer.
ASH
globenewswire.com
• Dec. 7, 2025
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time
FRO
globenewswire.com
• Dec. 7, 2025
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% for ibrutinib in the intent-to-treat (ITT) population Progression-free survival data were immature but trended in favor of pirtobrutinib with a 43% reduction of the risk of disease progression or death in the ITT population, and the treatment-naïve subgroup, which had the longest follow up, showed a 76% reduction These data will be simultaneously published in the Journal of Clinical Oncology and presented at the 2025 American Society of Hematology Annual Meeting and Exposition, as well as featured as part of the meeting's press program INDIANAPOLIS , Dec. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were treatment-naïve or were BTK inhibitor-naïve. Pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib (87.0% [95% CI, 82.90-90.44] versus 78.5% [95% CI, 73.73-82.85]; p1% of patients included pneumonia.
LLY
prnewswire.com
• Dec. 7, 2025
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
MLTX
newsfilecorp.com
• Dec. 7, 2025
Amazon has been a laggard the past few years. However, the company has been doing a lot right behind the scenes, including improving the operational efficiency of its e-commerce operations.
AMZN
fool.com
• Dec. 7, 2025
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub's September 2025 initial public offering (the "IPO"), of the important January 23, 2026 lead plaintiff deadline. SO WHAT: If you purchased StubHub common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
STUB
newsfilecorp.com
• Dec. 7, 2025
The share price of Snowflake dipped despite another strong quarter from the company. The company's growth is driven by the increasing need for AI to have clean, well-organized data.
SNOW
fool.com
• Dec. 7, 2025
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Marex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
MRX
newsfilecorp.com
• Dec. 7, 2025
/PRNewswire/ -- С 4 по 7 декабря бренд Assembly Character Toys Blokees впервые принял участие в Brazil Comic Con Experience (CCXP). Blokees представили
prnewswire.com
• Dec. 7, 2025
/PRNewswire/ -- Vom 4. bis 7. Dezember gab die Assembly Character Toys-Marke Blokees ihr Debüt auf der Brazil Comic Con Experience (CCXP). Blokees präsentierte
prnewswire.com
• Dec. 7, 2025
Victory Fighting League CEO, Dan Anderson, talks about his New York-based company and the rise of MMA as a sport. He points to TKO Group (TKO) muscling a strong 2025 rally as a leading signal to consumer interest.
MMA
youtube.com
• Dec. 7, 2025
New York City-based Engine Capital Management sold 635,255 shares of Amentum worth about $15 million in the third quarter. The move marked an exit for Engine Capital, which reported holding no shares of Amentum as of September 30.
AMTM
fool.com
• Dec. 7, 2025
